Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Hydrocortisone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 2/20 | 0.94 |
| ▸ | HIF1A | Q16665 | 11/20 | 0.94 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.94 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.94 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.94 |
| ▸ | NR3C2 | P08235 | 4/20 | 0.94 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.94 |
| ▸ | SERPINA6 | P08185 | 3/20 | 0.94 |
| ▸ | PGR | P06401 | 2/20 | 0.94 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.94 |
| ▸ | SHBG | P04278 | 2/20 | 0.94 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.94 |
| ▸ | MAPT | P10636 | 2/20 | 0.94 |
| ▸ | LMNA | P02545 | 3/20 | 0.79 |
| ▸ | AR | P10275 | 1/20 | 0.77 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.77 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.69 |
| ▸ | TSHR | P16473 | 2/20 | 0.69 |
| ▸ | BLM | P54132 | 1/20 | 0.69 |
| ▸ | POLB | P06746 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrocortisone SCHEMBL7420 | 1.00 | HIF1A (0.94) | HIF1AHSD17B10SMN1; SMN2CYP3A4NR3C2 | |
| Hydrocortisone SCHEMBL9622820 | 1.00 | HIF1A (0.94) | HIF1AHSD17B10SMN1; SMN2CYP3A4NR3C2 | |
| Hydrocortisone SCHEMBL8164979 | 0.97 | HIF1A (0.96) | HIF1AHSD17B10SMN1; SMN2CYP3A4NR3C2 | |
| Hydrocortisone SCHEMBL3999007 | 0.97 | HIF1A (0.96) | HIF1AHSD17B10SMN1; SMN2CYP3A4NR3C2 | |
| Hydrocortisone SCHEMBL24900238 | 0.97 | HIF1A (1.00) | HIF1AHSD17B10SMN1; SMN2CYP3A4NR3C2 | |
| Hydrocortisone SCHEMBL143923 | 0.97 | HIF1A (1.00) | HIF1AHSD17B10SMN1; SMN2CYP3A4NR3C2 | |
| Hydrocortisone SCHEMBL6932400 | 0.97 | HIF1A (1.00) | HIF1AHSD17B10SMN1; SMN2CYP3A4NR3C2 | |
| Hydrocortisone SCHEMBL5699764 | 0.97 | HIF1A (1.00) | HIF1AHSD17B10SMN1; SMN2CYP3A4NR3C2 | |
| Hydrocortisone SCHEMBL12737556 | 0.97 | HIF1A (1.00) | HIF1AHSD17B10SMN1; SMN2CYP3A4NR3C2 | |
| Hydrocortisone SCHEMBL10261067 | 0.97 | HIF1A (1.00) | HIF1AHSD17B10SMN1; SMN2CYP3A4NR3C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10646444-B2 | Method of preparing biologically formulations active | NORTEC DEVELOPMENT ASSOCIATES, INC. (US) | 2020-05-12 | — | — | US | disclosed |
| EP-1753398-B1 | CONTROLLED RELEASE MATRIX PHARMACEUTICAL DOSAGE FORMULATION | GLATT AIR TECHNIQUES INC (US) | 2018-09-19 | — | — | EP | disclosed |
| US-10039717-B2 | Method of preparing biologically active formulations | NORTEC DEVELOPMENT ASSOCIATES, INC. (US) | 2018-08-07 | — | — | US | disclosed |
| US-9687451-B2 | Controlled release matrix pharmaceutical dosage formulation | GLATT AIR TECHNIQUES, INC. (US) | 2017-06-27 | — | — | US | disclosed |
| US-20160220491-A1 | Method of Preparing Biologically Formulations Active | NORTEC DEVELOPMENT ASSOCIATES INC. (US) | 2016-08-04 | — | — | US | disclosed |
| US-9107804-B2 | Method of preparing biologically active formulations | NORTEC DEVELOPMENT ASSOCIATES, INC. (US) | 2015-08-18 | — | — | US | disclosed |
| US-9095601-B2 | Cell permeable nanoconjugates of shell-crosslinked knedel (SCK) and peptide nucleic acids (“PNAs”) with uniquely expressed or over-expressed mRNA targeting sequences for early diagnosis and therapy of cancer | WASHINGTON UNIVERSITY IN ST. LOUIS (US) | 2015-08-04 | — | — | US | disclosed |
| EP-1590144-B1 | METHOD OF PREPARING BIOLOGICALLY ACTIVE FORMULATIONS | NORTEC DEV ASS (US) | 2015-07-29 | — | — | EP | disclosed |
| US-20140255594-A1 | METHOD OF PREPARING BIOLOGICALLY ACTIVE FORMULATIONS | NORTEC DEVELOPMENT ASSOCIATES INC. (US) | 2014-09-11 | — | — | US | disclosed |
| US-20130230452-A1 | CELL PERMEABLE NANOCONJUGATES OF SHELL-CROSSLINKED KNEDEL (SCK) AND PEPTIDE NUCLEIC ACIDS (\"PNAs\") WITH UNIQUELY EXPRESSED OR OVER-EXPRESSED mRNA TARGETING SEQUENCES FOR EARLY DIAGNOSIS AND THERAPY OF CANCER | WASHINGTON UNIVERSITY (US) | 2013-09-05 | — | — | US | disclosed |
| EP-1590144-A1 | METHOD OF PREPARING BIOLOGICALLY ACTIVE FORMULATIONS | CPS Orocel LLC c/o Nadborny & Brinberg LLC (US) | 2005-11-02 | — | — | EP | disclosed |
| US-20040185111-A1 | pellet for use as a core for a dosage form, having an inner zone that includes the drug and an outer zone which includes a layer formed by applying a substantially dry, free flowing inert powder which forms a non-tacky surface in water; made with use of a rotating device | NORTEC DEVELOPMENT ASSOCIATES, INC. | 2004-09-23 | — | — | US | disclosed |
| WO-2004052607-A1 | METHOD OF PREPARING BIOLOGICALLY ACTIVE FORMULATIONS | CPS OROCEL LLC (US) | 2004-06-24 | — | — | WO | disclosed |
| US-6491903-B1 | NARROW MOLECULAR WEIGHT DISTRIBUTION SHELL-CORE POLYMERS HAVING HYDROPHILIC, CROSSLINKED PERMEABLE SHELLS AND HYDROPHOBIC CORES, USED FOR REDUCING BLOOD CHOLESTEROL AND BILE ACID UPTAKE IN INTERSTINES; DRUG DELIVERY | WASHINGTON UNIVERSITY | 2002-12-10 | — | — | US | disclosed |
| US-6383500-B1 | Particles comprising amphiphilic copolymers, having a crosslinked shell domain and an interior core domain, useful for pharmaceutical and other applications | WASHINGTON UNIVERSITY | 2002-05-07 | — | — | US | disclosed |
| EP-0910351-A1 | PARTICLES COMPRISING AMPHIPHILIC COPOLYMERS, HAVING A CROSS-LINKED SHELL DOMAIN AND AN INTERIOR CORE DOMAIN, USEFUL FOR PHARMACEUTICAL AND OTHER APPLICATIONS | G.D. Searle & Co. (US) | 1999-04-28 | — | — | EP | disclosed |
| EP-0907666-A1 | PARTICLES COMPRISING AMPHIPHILIC COPOLYMERS, HAVING A CROSS-LINKED SHELL DOMAIN AND AN INTERIOR CORE DOMAIN, USEFUL FOR PHARMACEUTICAL AND OTHER APPLICATIONS | G.D. Searle & Co. (US) | 1999-04-14 | — | — | EP | disclosed |
| WO-1997049736-A2 | PARTICLES COMPRISING AMPHIPHILIC COPOLYMERS, HAVING A CROSS-LINKED SHELL DOMAIN AND AN INTERIOR CORE DOMAIN, USEFUL FOR PHARMACEUTICAL AND OTHER APPLICATIONS | G.D. SEARLE AND CO. (US) | 1997-12-31 | — | — | WO | disclosed |
| WO-1997049387-A1 | PARTICLES COMPRISING AMPHIPHILIC COPOLYMERS, HAVING A CROSS-LINKED SHELL DOMAIN AND AN INTERIOR CORE DOMAIN, USEFUL FOR PHARMACEUTICAL AND OTHER APPLICATIONS | G.D. SEARLE AND CO. (US) | 1997-12-31 | — | — | WO | disclosed |
| US-5082668-A | Osmotic drug delivery | ALZA CORPORATION (US) | 1992-01-21 | — | — | US | disclosed |